Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year

Journal of Urology

Volumn 164, Issue 4, 2000, Pages 1197-1200

  Hatzichristou, Dimitrios G ^a   Apostolidis, Apostolos ^a   Tzortzis, Vasilios ^a   Ioannides, Evangelos ^a   Yannakoyorgos, Konstantinos ^a   Kalinderis, Athanasios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Impotence; Penis; Vasodilator agents

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033817436     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67140-6     Document Type: Article

References (15)

1. Intracavernous injection therapy for male erectile dysfunction
2. Current treatment and future perspectives for erectile dysfunction
3. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: Long-term dropout parameters
4. Oral sildenafil in the treatment of erectile dysfunction
5. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction
6. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience
7. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases
8. Long-term follow-up of patients receiving injection therapy for erectile dysfunction
9. Quality of life effects of alprostadil therapy for erectile dysfunction: Results of a trial in Europe and South Africa
10. Predictors of success and risk factors for attrition in the use of intracavernous injection
11. Reasons for discontinuing intracavernous injection therapy with prostaglandin E1 (alprostadil)
12. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease
13. Diffuse veno-occlusive dysfunction: The underlying hemodynamic abnormality resulting in failure to respond to intracavernous pharmacotherapy
14. Mechanisms of venous leakage: A prospective clinicopathological correlation of corporeal function and structure
15. Comparison of alprostadil sterile powder (Caverject) with trimix: Nomogram and patient satisfaction